BCM
ISEE

BlueCrest Capital Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

BlueCrest Capital Management’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,387
Closed -$37K – 1142
2017
Q2 		$37K Buy
+14,387
New +$39.2K ﹤0.01% 869

Other funds holding ISEE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

BlueCrest Capital Management's ISEE Position: Q3 2017 in Review

BlueCrest Capital Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2017, closing a stake of 14,387 shares — an estimated $37K sold.

BlueCrest Capital Management first reported a position in ISEE in Q2 2017 and held it in 1 quarter. The position peaked at $37K in Q2 2017. 67 funds tracked by Wall St. Rank hold ISEE as of Q3 2017.

  • BlueCrest Capital Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,387 IVERIC bio, Inc. Common Stock shares in Q3 2017, an estimated $37K.
  • BlueCrest Capital Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's IVERIC bio, Inc. Common Stock position peaked at $37K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2017.

Based on BlueCrest Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.